Renalys Pharma reports major phase III success for Sparsentan in Japanese IgA nephropathy patients
The study, which enrolled 35 Japanese patients, evaluated the percent change from baseline in the 24-hour urine protein-to-creatinine ratio
The study, which enrolled 35 Japanese patients, evaluated the percent change from baseline in the 24-hour urine protein-to-creatinine ratio
Renalyx will continue operating as an independent unit within the group
Deceased donor kidney transplants are time-critical, and it is uncommon to attempt them robotically
The ALLEGORY study demonstrated statistically significant improvements in key measures, including British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response
The upcoming state-of-the art 400+ bed facility is set to come up at an approximate cost of Rs 500 crore
The complex four-hour surgery was performed by a multidisciplinary team of doctors
Tolvaptan is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
Experts urge early detection & better access to care
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
Subscribe To Our Newsletter & Stay Updated